Ramachandra Reddy, MD
Hematology & Oncology · Valhalla, NYNPI 1689037616
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $535 of the $890 with a category attached, or 60.1%. Abiomed accounts for 60.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $607 and has fallen 71.9% since, to $171 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 13 payments — averaging $68.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$535
- Novartis$164
- Takeda Pharmaceuticals U.S.A., Inc.$55
- Octapharma USA, Inc.$34
- AstraZeneca$34
- Bristol Myers Squibb$27
- plus $41 from 2 others
What the payments were for
- Travel & lodging$53560%
- Food & beverage$35540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 1 | $535 |
| Novartis | 4 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Octapharma USA, Inc. | 1 | $34 |
| AstraZeneca | 1 | $34 |
| Bristol Myers Squibb | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$890 in reported general payments places this provider in the 40th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $12,815 |
| Enoxaparin Sodium | 15 | $2,923 |
| Mirtazapine | 29 | $427 |
| Anastrozole | 19 | $179 |
| Pantoprazole Sodium | 28 | $163 |
| Gabapentin | 14 | $121 |
| Letrozole | 11 | $119 |
| Oxycodone Hcl | 18 | $60 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Valhalla
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.